| Literature DB >> 33328475 |
Yfat Yahalom-Ronen1, Hadas Tamir1, Sharon Melamed1, Boaz Politi1, Ohad Shifman1, Hagit Achdout1, Einat B Vitner1, Ofir Israeli1, Elad Milrot1, Dana Stein1, Inbar Cohen-Gihon1, Shlomi Lazar1, Hila Gutman1, Itai Glinert1, Lilach Cherry1, Yaron Vagima1, Shirley Lazar1, Shay Weiss1, Amir Ben-Shmuel1, Roy Avraham1, Reut Puni1, Edith Lupu1, Elad Bar-David1, Assa Sittner1, Noam Erez1, Ran Zichel1, Emanuelle Mamroud1, Ohad Mazor1, Haim Levy1, Orly Laskar1, Shmuel Yitzhaki1, Shmuel C Shapira1, Anat Zvi1, Adi Beth-Din1, Nir Paran2, Tomer Israely3.
Abstract
The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.Entities:
Year: 2020 PMID： 33328475 DOI： 10.1038/s41467-020-20228-7
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919